Capivasertib — a new agent in the treatment algorithm for patients with advanced, metastatic HR-positive, HER2-negative breast cancer harboring genetic alterations in the PIK3CA/AKT1/PTEN genes
Oncology in Clinical Practice · 15.01.2026 · 22
DOI: 10.5603/ocp.111079 ↗Kurz gefasst
Fachartikel in der Zeitschrift Oncology in Clinical Practice, online erschienen am 15.01.2026. Verfasst von Tomasz Kubiatowski und 2 weiteren Autor:innen.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Kubiatowski, T., Kowalik, A., & Dubiański, R. (2026). Capivasertib — a new agent in the treatment algorithm for patients with advanced, metastatic HR-positive, HER2-negative breast cancer harboring genetic alterations in the PIK3CA/AKT1/PTEN genes. Oncology in Clinical Practice, 22(0). https://doi.org/10.5603/ocp.111079
Vancouver
Kubiatowski T, Kowalik A, Dubiański R. Capivasertib — a new agent in the treatment algorithm for patients with advanced, metastatic HR-positive, HER2-negative breast cancer harboring genetic alterations in the PIK3CA/AKT1/PTEN genes. Oncology in Clinical Practice. 2026;22(0). doi:10.5603/ocp.111079
BibTeX
@article{Kubiatowski2026,
author = {Kubiatowski, Tomasz and Kowalik, Artur and Dubiański, Roman},
title = {Capivasertib — a new agent in the treatment algorithm for patients with advanced, metastatic HR-positive, HER2-negative breast cancer harboring genetic alterations in the PIK3CA/AKT1/PTEN genes},
journal = {Oncology in Clinical Practice},
year = {2026},
volume = {22},
number = {0},
doi = {10.5603/ocp.111079}
}
EUVIMED